Medically reviewed by Ashley Baumohl, RD People with Crohn's disease are at an increased risk of certain nutrient ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

There can be no assurance regarding the schedule for completion of ... receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic ...

We put 13 top models to the test — discover which one torched the competition thanks to its affordability, versatility and effectiveness.

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third ...